NasdaqGS - Nasdaq Real Time Price USD

Repligen Corporation (RGEN)

167.82 -3.46 (-2.02%)
As of 10:54 AM EDT. Market Open.
Loading Chart for RGEN
DELL
  • Previous Close 171.28
  • Open 169.82
  • Bid 167.30 x 100
  • Ask 168.27 x 100
  • Day's Range 167.77 - 173.41
  • 52 Week Range 110.45 - 211.13
  • Volume 113,707
  • Avg. Volume 523,048
  • Market Cap (intraday) 9.371B
  • Beta (5Y Monthly) 1.01
  • PE Ratio (TTM) 226.79
  • EPS (TTM) 0.74
  • Earnings Date May 1, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 204.62

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

www.repligen.com

1,783

Full Time Employees

December 31

Fiscal Year Ends

Recent News: RGEN

Performance Overview: RGEN

Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

RGEN
6.66%
S&P 500
6.25%

1-Year Return

RGEN
1.04%
S&P 500
22.61%

3-Year Return

RGEN
23.13%
S&P 500
21.24%

5-Year Return

RGEN
193.14%
S&P 500
72.76%

Compare To: RGEN

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: RGEN

Valuation Measures

Annual
As of 4/23/2024
  • Market Cap

    9.56B

  • Enterprise Value

    9.52B

  • Trailing P/E

    231.46

  • Forward P/E

    119.05

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    15.12

  • Price/Book (mrq)

    4.85

  • Enterprise Value/Revenue

    14.91

  • Enterprise Value/EBITDA

    70.99

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    6.51%

  • Return on Assets (ttm)

    1.31%

  • Return on Equity (ttm)

    2.14%

  • Revenue (ttm)

    638.76M

  • Net Income Avi to Common (ttm)

    41.58M

  • Diluted EPS (ttm)

    0.74

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    751.32M

  • Total Debt/Equity (mrq)

    36.11%

  • Levered Free Cash Flow (ttm)

    71.08M

Research Analysis: RGEN

Analyst Price Targets

160.00
204.62 Average
167.82 Current
225.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Company Insights: RGEN

Fair Value

167.82 Current
 

Dividend Score

0 Low
RGEN
Sector Avg.
100 High
 

Hiring Score

0 Low
RGEN
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
RGEN
Sector Avg.
100 High
 

Research Reports: RGEN

  • RGEN: Lowering target price to $172.00

    REPLIGEN CORP has an Investment Rating of HOLD; a target price of $172.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Low.

    Rating
    Price Target
     
  • RGEN: Raising target price to $191.00

    REPLIGEN CORP has an Investment Rating of HOLD; a target price of $191.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Low.

    Rating
    Price Target
     
  • RGEN: Lowering target price to $187.00

    REPLIGEN CORP has an Investment Rating of HOLD; a target price of $187.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.

    Rating
    Price Target
     
  • RGEN: Lowering target price to $193.00

    REPLIGEN CORP has an Investment Rating of HOLD; a target price of $193.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.

    Rating
    Price Target
     

People Also Watch